Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Fabtech Technologies Limited is a turnkey life‑sciences engineering platform that designs, engineers, manufactures and validates Process, Air and Water systems for pharmaceutical, biotech and healthcare facilities, delivering start‑to‑finish GMP‑compliant projects across 62 countries with proprietary in‑house manufacturing and project execution capabilities.
The company reported nine‑month FY26 total income of ₹26,309.11 lakhs, but EBITDA and net profit declined materially year‑on‑year due to shipment‑timing effects and front‑loaded project costs, illustrating how shipment‑based revenue recognition can distort quarterly margins despite rising execution activity on the ground.
Fabtech’s business is heavily export‑oriented (management cites ~78% revenue from MENA/GCC/ECO markets) and benefits from structural tailwinds as emerging markets pursue pharmaceutical self‑reliance; current order book stands at approximately ₹926 crores (31 January 2026) with a $455 million hot‑lead pipeline supporting near‑term revenue visibility.
The company successfully completed an IPO raising ₹230.29 crores and retains substantial unutilized proceeds earmarked largely for working capital and inorganic growth, giving Fabtech the financial firepower to fund acquisitions, accelerate conversion, and pursue larger ticket, full‑scope turnkey projects across priority geographies.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
704 Cr
Moderate Risk
18.4
41.7
1.0
1.7
262.40
126.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
503.80 | 896 Cr | 30.68 | 4.41 | 0.00 | 14.31 | 18.03 | 8.19 | ||
158.40 | 704 Cr | 18.36 | 1.68 | 0.38 | 9.14 | 10.71 | 5.87 | ||
374.25 | 649 Cr | 63.39 | 3.73 | 0.00 | 5.88 | 7.65 | 5.02 | ||
377.00 | 548 Cr | 30.13 | 3.28 | 0.00 | 13.22 | 14.71 | 6.63 | ||
393.80 | 472 Cr | 23.05 | 3.78 | 0.00 | 16.42 | 22.13 | 15.38 | ||
160.00 | 305 Cr | 59.73 | 4.39 | 0.00 | 7.35 | 14.27 | 6.24 | ||
122.75 | 304 Cr | 33.59 | 3.06 | 0.41 | 9.10 | 12.59 | 7.84 | ||
| Median: 7 Co. | — | 374.25 | 548 Cr | 30.68 | 3.73 | 0.00 | 9.14 | 14.27 | 6.63 |
Fabtech Technologies Ltd (FABTECH) is currently trading at 158.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fabtech Technologies Limited is a turnkey life‑sciences engineering platform that designs, engineers, manufactures and validates Process, Air and Water systems for pharmaceutical, biotech and healthcare facilities, delivering start‑to‑finish GMP‑compliant projects across 62 countries with proprietary in‑house manufacturing and project execution capabilities. The company reported nine‑month FY26 total income of ₹26,309.11 lakhs, but EBITDA and net profit declined materially year‑on‑year due to shipment‑timing effects and front‑loaded project costs, illustrating how shipment‑based revenue recognition can distort quarterly margins despite rising execution activity on the ground. Fabtech’s business is heavily export‑oriented (management cites ~78% revenue from MENA/GCC/ECO markets) and benefits from structural tailwinds as emerging markets pursue pharmaceutical self‑reliance; current order book stands at approximately ₹926 crores (31 January 2026) with a $455 million hot‑lead pipeline supporting near‑term revenue visibility. The company successfully completed an IPO raising ₹230.29 crores and retains substantial unutilized proceeds earmarked largely for working capital and inorganic growth, giving Fabtech the financial firepower to fund acquisitions, accelerate conversion, and pursue larger ticket, full‑scope turnkey projects across priority geographies.
Over the past 52 weeks, Fabtech Technologies Ltd has traded between a low of ₹126.00 and a high of ₹262.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fabtech Technologies Ltd has a market capitalization of approximately 704.10. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fabtech Technologies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.36 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 704.10 Cr, Fabtech Technologies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fabtech Technologies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fabtech Technologies Ltd is 18.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
6
Neutral
5
Bullish
3
Bearish
9
Neutral
9
Bullish
28
Bearish
3
Neutral
4
Bullish
25
Contract Award
Fabtech Technologies Ltd (15 Jun 2026) secured a ₹31.23 crore contract to deliver GMP‑compliant internal infrastructure (HVAC, clean utilities, MEP) for a new veterinary vaccine manufacturing facility in Botswana.
Contract Award
Fabtech Technologies secured a ₹31.23 crore contract to deliver GMP‑compliant internal infrastructure, precision HVAC, clean utilities and MEP services for a veterinary vaccine manufacturing facility in Botswana.
Order/Contract Award
Fabtech Technologies received a turnkey order from Botswana Vaccine Institute to design, supply, install and commission HVAC and clean-room systems for a blending & filling project worth ~USD 3.303M (≈Rs 31.23 Cr), to be executed within 14 months.
Contract Award
On June 15, 2026 Fabtech secured an international turnkey contract from Botswana Vaccine Institute to design, supply, install, test and commission clean rooms and HVAC for a blending & filling project; value USD ~3.303M (≈Rs 31.23 Cr), execution up to 14 months.
